Prophylaxis News and Research

RSS

SARS-CoV-2 oral vaccine candidate found to induce neutralizing mucosal IgA

A new study reported the outcomes of a clinical trial evaluating the oral vaccine candidate against SARS-CoV-2 developed by Vaxart.

25 Jul 2022

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

AbbVie today announced it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.

From AbbVie 21 Jul 2022

Researchers describe viral shedding of monkeypox virus in patients to better understand the possible role of different bodily fluids in disease transmission

Researchers described the shedding of the monkeypox (MPX) virus (MPXV) in Barcelona city of Spain.

20 Jul 2022

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

AbbVie today announced it has submitted a marketing authorization application to the European Medicines Agency for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.

From AbbVie 19 Jul 2022

Epidemiologic features of the June 2022 monkeypox outbreak in Spain

Researchers described epidemiologic features of monkeypox cases reported in Spain and the intervention measures taken to control the outbreak.

14 Jul 2022

The potential of tixagevimab–cilgavimab for treating hospitalized COVID-19 patients

Scientists assessed the potential of tixagevimab–cilgavimab for treating hospitalized SARS-CoV-2 patients.

13 Jul 2022

Researchers investigate prevention and therapy against monkeypox infection

Researchers reviewed the preventive and therapeutic measures against monkeypox.

4 Jul 2022

The importance of smallpox vaccination as a preventive measure in controlling recent outbreaks of monkeypox

Scientists have described the importance of smallpox vaccination as a preventive measure in controlling recent outbreaks of monkeypox infection.

4 Jul 2022

CDC data shows a sharp decrease in HIV testing during first year of COVID-19 pandemic

New CDC data published ahead of National HIV Testing Day (Monday, June 27) show a sharp decrease in the number of CDC-funded HIV tests administered in health care and non-health-care settings (43% and 50%, respectively) from 2019 to 2020, the first year of the COVID-19 pandemic.

28 Jun 2022

Bisphosphonates appear to improve COVID-19 exposure outcomes

A new retrospective study examines the effect of bisphosphonates on COVID-19 outcomes.

27 Jun 2022

Research assesses ability of SARS‐CoV‐2‐neutralising mAbs to prevent COVID‐19

In a recent study published in the Cochrane Library, researchers searched multiple databases to identify randomized controlled trials (RCTs) that evaluated severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐neutralizing monoclonal antibodies (mAbs).

23 Jun 2022

COVID-19 outcomes improved for SARDs patients through Omicron wave

In a recent study posted to the medRxiv* pre-print server, researchers investigated coronavirus disease 2019 (COVID-19) incidence and severity among systemic autoimmune rheumatic diseases (SARDs) patients in Massachusetts, United States (US), between March 1, 2020, and January 31, 2022.

22 Jun 2022

Researchers assess monkeypox clinical management guidelines worldwide

A new study demonstrated the scarcity of appropriate clinical management guidelines for monkeypox infections across the globe.

20 Jun 2022

Illustrating a rapid response approach for monkeypox management

Researchers illustrated a rapid response strategy for managing monkeypox outbreaks.

20 Jun 2022

Fc-effector functions for selecting COVID-19 convalescent plasma

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated that coronavirus disease 2019 (COVID-19) convalescent plasmas (CCPs) with low neutralizing and high fragment crystallizable (Fc)-effector activity result in effective prophylaxis.

15 Jun 2022

Two broadly neutralizing antibodies show promise to provide long-acting immunity against SARS-CoV-2

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM).

15 Jun 2022

Population-level big data reveals COVID-19 phenotypes

A recent study published in The Lancet Digital Health journal assessed the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection trajectories in England utilizing electronic health records (EHRs).

13 Jun 2022

The effectiveness of tixagevimab/cilgavimab for prevention of SARS-CoV-2 infection and severe disease among immunocompromised patients

A recent article assessed the potency of tixagevimab/cilgavimab in averting SARS-CoV-2 infection in vaccinated immunocompromised people.

31 May 2022

Evaluating tixagevimab plus cilgavimab against SARS-CoV-2

Researchers assessed the neutralizing activity against SARS-CoV-2 Omicron variant after tixagevimab plus cilgavimab (T+C) administration.

30 May 2022

A polymer-nanoparticle hydrogel to subcutaneously deliver broadly neutralizing antibodies against SARS-CoV-2

Researchers compared the polymer-nanoparticle hydrogel system and standard routes of delivery of broadly neutralizing antibodies against SARS-CoV-2 in a mouse model.

27 May 2022

Prophylaxis News and Research

SARS-CoV-2 oral vaccine candidate found to induce neutralizing mucosal IgA

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

Researchers describe viral shedding of monkeypox virus in patients to better understand the possible role of different bodily fluids in disease transmission

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

Epidemiologic features of the June 2022 monkeypox outbreak in Spain

The potential of tixagevimab–cilgavimab for treating hospitalized COVID-19 patients

Researchers investigate prevention and therapy against monkeypox infection

The importance of smallpox vaccination as a preventive measure in controlling recent outbreaks of monkeypox

CDC data shows a sharp decrease in HIV testing during first year of COVID-19 pandemic

Bisphosphonates appear to improve COVID-19 exposure outcomes

Research assesses ability of SARS‐CoV‐2‐neutralising mAbs to prevent COVID‐19

COVID-19 outcomes improved for SARDs patients through Omicron wave

Researchers assess monkeypox clinical management guidelines worldwide

Illustrating a rapid response approach for monkeypox management

Fc-effector functions for selecting COVID-19 convalescent plasma

Two broadly neutralizing antibodies show promise to provide long-acting immunity against SARS-CoV-2

Population-level big data reveals COVID-19 phenotypes

The effectiveness of tixagevimab/cilgavimab for prevention of SARS-CoV-2 infection and severe disease among immunocompromised patients

Evaluating tixagevimab plus cilgavimab against SARS-CoV-2

A polymer-nanoparticle hydrogel to subcutaneously deliver broadly neutralizing antibodies against SARS-CoV-2

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News